pubmed.ncbi.nlm.nih.gov

Substitution of red meat with soybean but not non- soy legumes improves inflammation in patients with type 2 diabetes; a randomized clinical trial - PubMed

  • ️Mon Jan 01 2018

Substitution of red meat with soybean but not non- soy legumes improves inflammation in patients with type 2 diabetes; a randomized clinical trial

Zeynab Hematdar et al. J Diabetes Metab Disord. 2018.

Abstract

Background and aims: Several studies have documented that consumption of legumes including soybean is inversely associated with systemic inflammation and oxidative stress. This study was done to assess the effects of soy beans or non-soy legumes consumption on C-reactive protein (CRP) and malondialdehyde (MDA) among Patients with Type 2 Diabetes (T2D).

Methods: 75 persons with T2D participated in this randomized controlled clinical trial. Participants were randomized to one of the following 3 groups for 8 weeks: soy bean group (taking a cup of cooked soy beans three days a week), legumes group (taking a cup of cooked non-soy legumes three days a week) and control group (taking two servings of red meat three days a week). Anthropometric indices, dietary intakes, and serum MDA and CRP were measured at baseline and after intervention.

Results: A Significant decrease was observed in serum CRP of soy bean group (P = 0.01) which was significantly more than the controls (p = 0.001), while no significant changes of CRP was observed in legume group. Serum MDA changed significantly in none of the 3 groups.

Conclusions: In conclusion, we found that substitution of red meat with soybean but not non- soy legumes may reduce inflammatory factors with no effects on oxidative stress in diabetic patients.

Keywords: Diabetes; Inflammation; Legumes; Oxidative stress; Soybean.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standardsThe authors declared that they have no conflict of interest.

Figures

Fig. 1
Fig. 1

Participant flow diagram throughout the study

Similar articles

Cited by

References

    1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149. doi: 10.1016/j.diabres.2013.11.002. - DOI - PubMed
    1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi: 10.1016/j.diabres.2009.10.007. - DOI - PubMed
    1. Mannucci E, Dicembrini I, Lauria A, Pozzilli P. Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care. 2013;36(Suppl 2):S259–S263. doi: 10.2337/dcS13-2018. - DOI - PMC - PubMed
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi: 10.1056/NEJMoa0806470. - DOI - PubMed
    1. Committee PP, Classification A. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(Suppl 1):S11–61. - PMC - PubMed